ILDONG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15,440 KRW | -1.40% |
|
-0.77% | -14.98% |
| 2023 | Il Dong Pharmaceutical Eyes Approval for to Manufacture Japan's COVID-19 Treatment in South Korea | MT |
| 2023 | Il Dong Pharmaceutical Introduces New R&D Unit Yunovia | MT |
Valuation
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,79,499 | 7,64,721 | 5,02,483 | 4,31,276 | - | - |
| Enterprise Value (EV) 1 | 3,79,542 | 7,64,721 | 5,02,483 | 4,31,276 | 4,31,276 | 4,31,276 |
| P/E ratio | - | - | - | 11.2 x | 8.05 x | 7.19 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.73 x | 1.2 x | 0.84 x | 0.69 x | 0.63 x | 0.59 x |
| EV / Revenue | 0.73 x | 1.2 x | 0.84 x | 0.69 x | 0.63 x | 0.59 x |
| EV / EBITDA | 14.7 x | -17.8 x | - | 5.07 x | 4.07 x | 3.85 x |
| EV / FCF | 13.4 x | - | - | 8.63 x | 6.64 x | 6.25 x |
| FCF Yield | 7.48% | - | - | 11.6% | 15.1% | 16% |
| Price to Book | 1.44 x | - | - | 2.09 x | 1.66 x | 1.35 x |
| Nbr of stocks (in thousands) | 23,790 | 26,785 | 27,670 | 27,932 | - | - |
| Reference price 2 | 15,952 | 28,550 | 18,160 | 15,440 | 15,440 | 15,440 |
| Announcement Date | 14/02/20 | 09/02/23 | 08/02/24 | - | - | - |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 516.8 | 635.8 | 597.9 | 626 | 685.5 | 726 |
| EBITDA 1 | 25.73 | -42.98 | - | 85 | 106 | 112 |
| EBIT 1 | -1.901 | -72.15 | -40.91 | 59.3 | 82.2 | 89 |
| Operating Margin | -0.37% | -11.35% | -6.84% | 9.47% | 11.99% | 12.26% |
| Earnings before Tax (EBT) 1 | - | - | -82.04 | 47.5 | 67.3 | 75 |
| Net income 1 | - | - | -71.49 | 38.8 | 53.8 | 60 |
| Net margin | - | - | -11.96% | 6.2% | 7.85% | 8.26% |
| EPS 2 | - | - | - | 1,382 | 1,918 | 2,146 |
| Free Cash Flow 3 | 28,374 | - | - | 50,000 | 65,000 | 69,000 |
| FCF margin | 5,490.12% | - | - | 7,987.22% | 9,482.13% | 9,504.13% |
| FCF Conversion (EBITDA) | 1,10,256.09% | - | - | 58,823.53% | 61,320.75% | 61,607.14% |
| FCF Conversion (Net income) | - | - | - | 1,28,865.98% | 1,20,817.84% | 1,15,000% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 14/02/20 | 09/02/23 | 08/02/24 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q2 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|
| Net sales 1 | 162 | 149.4 | 150.7 | 154.2 | 159.1 | 162.1 |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -22.03 | - | 15.05 | 14.2 | 14.6 | 15.5 |
| Operating Margin | -13.6% | - | 9.99% | 9.21% | 9.18% | 9.56% |
| Earnings before Tax (EBT) 1 | - | 0.017 | 17.94 | 10.7 | 9.1 | 9.8 |
| Net income 1 | - | 7.501 | 13.62 | 9.1 | 7.8 | 8.3 |
| Net margin | - | 5.02% | 9.04% | 5.9% | 4.9% | 5.12% |
| EPS | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 27/07/22 | 08/02/24 | 09/05/24 | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | 42.5 | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 1.65 x | - | - | - | - | - |
| Free Cash Flow 1 | 28,374 | - | - | 50,000 | 65,000 | 69,000 |
| ROE (net income / shareholders' equity) | -5.13% | - | - | 20.9% | 23.2% | 20.8% |
| ROA (Net income/ Total Assets) | -2.31% | - | - | 6.7% | 8.9% | 9% |
| Assets 2 | - | - | - | 579.1 | 604.5 | 666.7 |
| Book Value Per Share 3 | 11,116 | - | - | 7,387 | 9,305 | 11,451 |
| Cash Flow per Share 3 | - | - | - | 2,291 | 2,773 | 2,954 |
| Capex 2 | 12 | - | - | 15 | 15 | 15 |
| Capex / Sales | 2.33% | - | - | 2.4% | 2.19% | 2.07% |
| Announcement Date | 14/02/20 | 09/02/23 | 08/02/24 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.98% | 315M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- A249420 Stock
- Financials Ildong Pharmaceutical Co., Ltd.